Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells $76,397.04 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 16,902 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the transaction, the chief operating officer now directly owns 216,250 shares of the company’s stock, valued at approximately $977,450. This trade represents a 7.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $5.76, for a total value of $30,003.84.
• On Monday, January 6th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $7.51, for a total value of $39,119.59.

Health Catalyst Stock Up 6.2 %

HCAT opened at $4.43 on Thursday. Health Catalyst, Inc. has a 1-year low of $3.76 and a 1-year high of $9.24. The stock’s fifty day simple moving average is $5.56 and its 200 day simple moving average is $7.10. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market cap of $311.03 million, a PE ratio of -3.28 and a beta of 1.41.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on HCAT shares. Stephens cut their price objective on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, March 6th. Wells Fargo & Company cut their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Citigroup cut their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Royal Bank of Canada cut their price objective on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. Finally, Piper Sandler cut their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.27.

Institutional Investors Weigh In On Health Catalyst

Large investors have recently added to or reduced their stakes in the business. Palogic Value Management L.P. bought a new position in Health Catalyst during the 4th quarter worth $2,262,000. Probity Advisors Inc. increased its position in Health Catalyst by 33.2% during the 4th quarter. Probity Advisors Inc. now owns 30,692 shares of the company’s stock worth $217,000 after buying an additional 7,647 shares during the period. Mackenzie Financial Corp bought a new position in Health Catalyst during the 4th quarter worth $248,000. PharVision Advisers LLC bought a new position in Health Catalyst during the 4th quarter worth $185,000. Finally, Two Sigma Advisers LP increased its position in Health Catalyst by 72.7% during the 4th quarter. Two Sigma Advisers LP now owns 29,700 shares of the company’s stock worth $210,000 after buying an additional 12,500 shares during the period. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.